Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IN8bio, Inc. (Nasdaq: INAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases, and its filings offer structured insight into this development activity and its status as a Nasdaq-listed issuer.
IN8bio uses Form 8-K current reports to announce material events such as clinical data updates, preclinical presentations and financial results. For example, the company has filed 8-Ks referencing presentations of INB-200 and INB-400 glioblastoma data at the Society for Neuro-Oncology (SNO) Annual Meeting, new preclinical data from its INB-619 γδ T cell engager program at the American College of Rheumatology (ACR) Convergence Meeting, and quarterly financial results press releases. Another 8-K documents Nasdaq’s confirmation that IN8bio regained compliance with the minimum bid price listing rule, and reiterates that its common stock trades on The Nasdaq Stock Market LLC under the symbol INAB.
Through IN8bio’s periodic reports and exhibits referenced in 8-Ks, investors can review information on research and development spending, general and administrative expenses, net loss, cash position and stockholders’ equity, as well as narrative descriptions of pipeline programs such as INB-100, INB-200, INB-400, INB-619 and the INB-600 platform. These filings also include risk factor discussions and forward-looking statements that frame the uncertainties inherent in clinical-stage biopharmaceutical development.
On Stock Titan, INAB filings are updated in line with new submissions to EDGAR. AI-powered tools can help summarize lengthy documents, highlight key clinical and financial disclosures, and surface specific items such as clinical trial updates embedded in exhibits to Form 8-K. Users interested in IN8bio’s regulatory and financial history can review this archive to track how the company describes its γδ T cell programs, manufacturing capabilities, Nasdaq listing status and other material developments over time.
IN8bio, Inc. files its annual report describing a focused gamma‑delta T cell therapy pipeline alongside a going concern warning. The company is developing allogeneic and autologous gamma‑delta T cell products and T cell engagers for cancers and autoimmune diseases, highlighted by INB‑100 for high‑risk leukemias and INB‑200/INB‑400 for newly diagnosed glioblastoma.
Early clinical data show durable remissions in AML patients after haploidentical transplants and extended progression‑free survival in glioblastoma versus standard therapy. IN8bio reported cash of
IN8bio, Inc. reported fourth quarter and full-year 2025 results, highlighting clinical progress in glioblastoma, a strengthened balance sheet and lower losses. Repeat dosing of its DeltEx DRI γδ T cells in newly diagnosed GBM achieved median progression-free survival of 13.0 months versus 6.6 months for a standard-of-care cohort, with no dose-limiting toxicities or serious unexpected safety issues reported.
The company closed an initial
IN8bio is advancing its INB-200/400 GBM programs, INB-100 for high-risk leukemias, and the INB-600 γδ T cell engager platform, including INB-619 heading into IND-enabling studies. The company outlined multiple 2026 milestones, including FDA guidance on regulatory pathways, additional GBM data and initial INB-619 animal data.
IN8BIO, Inc. reports that Laurence W. Lytton and the Lytton-Kambara Foundation each beneficially own
The filing states that the reported holdings "consist of 900,000 shares of Common Stock and warrants to purchase 1,092,753 shares of Common Stock, subject to a 9.99% beneficial ownership limitation," and that the percentage was calculated based on 9,766,132 shares outstanding as of
IN8bio, Inc. reported that director Alan S. Roemer has notified the Board of his decision to resign from the Board and from the Audit and Compensation Committees, effective February 28, 2026. The company states that his resignation is not due to any disagreement with IN8bio, its management, the Board, or any Board committee on matters related to operations, policies, or practices.
The Board has appointed independent director Jeremy Graff as Interim Chair of the Board, effective the same date. This change reflects a governance and leadership transition at the Board level without any financial results or major transactions described in this report.
IN8bio, Inc. received a Schedule 13G showing that Alyeska Investment Group, Alyeska Fund GP, and Anand Parekh beneficially own 966,381 shares of common stock, representing 9.9% of the class as of December 31, 2025. The group reports no sole voting or dispositive power, but shared power over all reported shares.
The filing explains that Alyeska-related entities hold common stock, PIPE shares, and warrants, but the warrants are subject to a 9.9% ownership cap. Based on 9,761,425 IN8bio shares outstanding, the reporting persons certify the holdings were acquired in the ordinary course and not to influence control.
IN8bio, Inc. announced that its Board of Directors appointed Chief Operating Officer Kate Rochlin as President of the company, effective February 4, 2026. She will hold both roles of President and Chief Operating Officer, providing continuity in executive leadership. The company notes that there are no family relationships or related-party transactions involving Dr. Rochlin that require disclosure under the SEC’s executive and related-party rules.
IN8bio, Inc. (INAB) reported an option grant to executive Lawrence Lamb, EVP and CSO. On February 4, 2026, he received 72,000 employee stock options with a $1.96 exercise price, all held directly. Twenty-five percent vest on February 4, 2027, with the remaining options vesting in 36 equal monthly installments, contingent on his continued service.
IN8bio, Inc. (INAB) granted its Chief Financial Officer, McCall Patrick, a new stock option award. On February 4, 2026, the CFO received an employee stock option to purchase 75,000 shares of common stock at an exercise price of $1.96 per share.
These options were awarded at no cost and are held directly. Twenty-five percent of the shares vest on February 4, 2027, and the remaining shares vest in 36 equal monthly installments afterward, as long as the CFO continues to provide service through each vesting date.
IN8bio, Inc. reported an equity award to its President and COO, Kate Rochlin, on a Form 4. On February 4, 2026, she received an employee stock option80,000 shares of common stock at an exercise price of $1.96 per share, held directly.
The option expires on February 4, 2036. Vesting is time-based: 25% of the option vests on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on her continued service with the company.
IN8bio, Inc. (INAB) reported a new stock option grant to CEO, director and 10% owner William Tai-Wei Ho. On February 4, 2026, he received an employee stock option206,000 shares of common stock at an exercise price of $1.96 per share, expiring February 4, 2036.
According to the vesting terms, 25% of the option shares vest on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, as long as he continues to provide service through each vesting date. Following this grant, he beneficially owns 206,000 derivative securities directly.